Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Remifentanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 14/20 | 0.76 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Remifentanil SCHEMBL3423820 | 1.00 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL29846323 | 1.00 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL3711219 | 1.00 | CACNA1C (0.98) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL36652 | 0.99 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL17874058 | 0.99 | CACNA1C (1.00) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL27828413 | 0.97 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL1649640 | 0.97 | CACNA1C (0.96) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL8446617 | 0.94 | CACNA1C (0.90) | CACNA1COPRM1OPRD1OPRK1 | |
| Carfentanil SCHEMBL16444962 | 0.93 | OPRM1 (0.89) | CACNA1COPRM1OPRD1OPRK1 | |
| Remifentanil SCHEMBL4384648 | 0.93 | CACNA1C (0.89) | CACNA1COPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025062440-A1 | TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF | PULSE PHARMACEUTICALS PVT. LTD (IN) | 2025-03-27 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-117664949-A | Detection method of surface-enhanced Raman nano particles and fentanyl substances | 深圳海关工业品检测技术中心 | 2024-03-08 | — | — | CN | claimed |
| US-20230312472-A1 | PROCESS FOR PREPARING REMIFENTANIL HYDROCHLORIDE | JOHNSON MATTHEY PUBLIC LIMITED (GB) | 2023-10-05 | — | — | US | claimed |
| EP-4175945-A1 | PROCESS FOR PREPARING REMIFENTANIL HYDROCHLORIDE | Macfarlan Smith Limited (GB) | 2023-05-10 | — | — | EP | claimed |
| CN-115996909-A | Process for preparing remifentanil hydrochloride | 麦克法伦史密斯有限公司 | 2023-04-21 | — | — | CN | claimed |
| US-11615892-B2 | Method for predicting risk of delirium and device for predicting risk of delirium using the same | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YOUNSEI UNIVERSITY (KR) | 2023-03-28 | — | — | US | claimed |
| CN-113376277-B | High-resolution mass spectrometry detection method for fentanyl drugs in health care products | 西安海关技术中心 | 2023-03-17 | — | — | CN | claimed |
| CN-109374791-B | Method for determining acid residue in remifentanil hydrochloride raw material by using high performance liquid chromatography | 宜昌人福药业有限责任公司 | 2022-06-03 | — | — | CN | claimed |
| WO-2022003364-A1 | PROCESS FOR PREPARING REMIFENTANIL HYDROCHLORIDE | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-01-06 | — | — | WO | claimed |
| WO-2007092143-A1 | CRYSTALLINE FORM OF REMIFENTANIL HYDROCHLORIDE | MALLINCKRODT INC. (US) | 2007-08-16 | — | — | WO | claimed |
| US-20060210632-A1 | Sublingual coated tablet of fentanyl | ETHYPHARM (FR) | 2006-09-21 | — | — | US | claimed |
| WO-2006097361-A1 | SUBLINGUAL COATED TABLET | ETHYPHARM (FR) | 2006-09-21 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1371369-A1 | Compositions comprising remifentanil | GLAXO GROUP LIMITED (GB) | 2003-12-17 | — | — | EP | claimed |
| EP-1158979-A2 | COMPOSITIONS OF REMIFENTANIL | GLAXO GROUP LIMITED (GB) | 2001-12-05 | — | — | EP | claimed |
| WO-2000051603-A2 | COMPOSITIONS OF REMIFENTANIL | GLAXO GROUP LIMITED (GB) | 2000-09-08 | — | — | WO | claimed |
| US-5866591-A | ASCORBIC ACID, CITRIC ACID, MALEIC ACID, PHOSPHORIC ACID, GLYCINE, SUCCINIC ACID, OR TARTARIC ACID, ROOM TEMPERATURE SHELF LIFE STABILITY OF AT LEAST TWO YEARS. | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312472-A1 | PROCESS FOR PREPARING REMIFENTANIL HYDROCHLORIDE | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885CACNA1C 3299/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.